{"id":26670,"date":"2024-09-17T11:26:51","date_gmt":"2024-09-17T09:26:51","guid":{"rendered":"https:\/\/ggba.swiss\/?p=26670"},"modified":"2024-09-17T12:05:35","modified_gmt":"2024-09-17T10:05:35","slug":"haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/","title":{"rendered":"HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.hayatx.com\/\">HAYA Therapeutics<\/a>, a leading Vaud-based biotech specializing in precision RNA-guided therapies, has entered into a major partnership with global pharmaceutical giant <a href=\"https:\/\/www.lilly.com\/\">Eli Lilly and Company<\/a>. The collaboration will utilize HAYA&#8217;s advanced regulatory genomics platform to identify RNA-based drug targets for obesity and related metabolic disorders and marks a major milestone in the company&#8217;s growth.<\/p>\n\n\n\n<p>Under the terms of the multi-year agreement, HAYA will receive an upfront payment, including an equity investment from Lilly, and is eligible to receive up to USD 1 billion in preclinical, clinical and commercial milestone payments, as well as royalties on future product sales. The partnership underscores the growing interest in HAYA&#8217;s unique approach to targeting long non-coding RNA (lncRNA) for the development of novel therapeutics.<\/p>\n\n\n\n<p>HAYA&#8217;s proprietary platform enables the identification of tissue-, disease- and cell-specific lncRNA targets, offering potentially more effective and less toxic treatments by reprogramming disease-driving cell states. The collaboration with Lilly will focus on identifying and validating multiple novel lncRNA targets for obesity and metabolic disorders, areas of significant unmet medical need.<\/p>\n\n\n\n<p>&#8220;This partnership with Lilly demonstrates the significant progress we have made with our revolutionary regulatory genome RNA-guided platform and validates the potential of targeting lncRNA for chronic diseases,&#8221; said Samir Ounzain, CEO of HAYA Therapeutics. &#8220;We look forward to working closely with Lilly to develop novel disease-modifying therapeutics that may offer greater efficacy, safety and accessibility than current treatments.&#8221;<\/p>\n\n\n\n<p>HAYA Therapeutics, headquartered at the <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le life sciences campus<\/a> in Lausanne and with laboratory facilities at JLABS in San Diego, continues to push the boundaries of precision medicine. The company&#8217;s lead therapeutic candidate, HTX-001, is in development for the treatment of heart failure, and HAYA is also advancing a pipeline of lncRNA-targeted therapies for cardiovascular, metabolic and cancer diseases. Ranked first in the <a href=\"https:\/\/ggba.swiss\/en\/haya-therapeutics-triumphs-at-the-13th-top-100-swiss-startup-award\/\">TOP 100 Swiss Startup Award for 2023<\/a>, this partnership with Lilly strengthens HAYA&#8217;s position as a key player in the field of RNA-guided therapies.<\/p>\n\n\n\n<p>With this collaboration, HAYA Therapeutics strengthens its innovative approach to the treatment of chronic diseases and highlights Western Switzerland&#8217;s importance in the life sciences and biotechnology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.<\/p>\n","protected":false},"author":6,"featured_media":26671,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,890,883,911,886],"class_list":["post-26670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-healthcare","tag-oncology","tag-pharma","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa<\/title>\n<meta name=\"description\" content=\"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa\" \/>\n<meta property=\"og:description\" content=\"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-17T09:26:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery\",\"datePublished\":\"2024-09-17T09:26:51+00:00\",\"dateModified\":\"2024-09-17T10:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\"},\"wordCount\":358,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\",\"url\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\",\"name\":\"HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png\",\"datePublished\":\"2024-09-17T09:26:51+00:00\",\"dateModified\":\"2024-09-17T10:05:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"HAYA Therapeutics leverages the power of the dark genome to develop precise and potent RNA therapies for reprogramming disease driving cell-states. | \u00a9 HAYA Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa","description":"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa","og_description":"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.","og_url":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-09-17T09:26:51+00:00","article_modified_time":"2024-09-17T10:05:35+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery","datePublished":"2024-09-17T09:26:51+00:00","dateModified":"2024-09-17T10:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/"},"wordCount":358,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png","keywords":["Biotech","Financing","Healthcare","Oncology","Pharma","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/","url":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/","name":"HAYA Therapteutics enters major collaboration with Eli Lilly | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png","datePublished":"2024-09-17T09:26:51+00:00","dateModified":"2024-09-17T10:05:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/09\/HAYA-Therapeutics-1180x811-1.png","width":1180,"height":811,"caption":"HAYA Therapeutics leverages the power of the dark genome to develop precise and potent RNA therapies for reprogramming disease driving cell-states. | \u00a9 HAYA Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/26670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=26670"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/26670\/revisions"}],"predecessor-version":[{"id":26690,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/26670\/revisions\/26690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/26671"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=26670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=26670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=26670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}